Form 4: Director Robert J. More Receives Vir Biotechnology Equity

Director Robert J. More acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Summary

• Director Robert J. More was granted 8,000 restricted stock units (RSUs) on May 27, 2026.
• The director also received a grant of 16,000 stock options with an exercise price of $9.10.
• Both the RSUs and the stock options are scheduled to vest in full on May 27, 2027.
• Following these transactions, the director holds 48,656 shares directly and maintains an indirect interest in 509,917 shares via Alta Partners NextGen Fund I, L.P.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard equity incentive plan utilization indicates normal corporate governance practices.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with corporate performance milestones.

Comparison to Industry Standards

• The grant of RSUs and options is consistent with standard compensation packages for non-employee directors in mid-cap biotechnology firms.
• The one-year cliff vesting schedule is a common retention mechanism used by companies like Vir Biotechnology to ensure long-term commitment from board members.

Related Party Transactions

• The reporting person is a managing director of the general partner of Alta Partners NextGen Fund I, L.P., which holds 509,917 shares.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of equity awards on May 27, 2027.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Equity Compensation, Director Compensation